Positron emission tomography to detect bone marrow involvement for patients with follicular lymphoma: a systematic review and meta-analysis

Ann Hematol. 2023 Sep;102(9):2403-2412. doi: 10.1007/s00277-023-05274-7. Epub 2023 May 20.

Abstract

Detection of bone marrow involvement (BMI) for patients with follicular lymphoma (FL) is of great significance for staging and treatment. The clinical value of positron emission tomography/computed tomography (PET/CT) in assessing BMI is still under debate and investigation. PubMed, Embase, Web of Science, and Cochrane Library databases were systematically searched to identify studies evaluating PET/CT in detecting BMI in FL patients. Data extraction and quality evaluation were independently conducted by two reviewers, and nine eligible studies were selected as final quantitative analysis. Nine studies comprising 1119 FL patients were included. The pooled sensitivity was 0.67 (95% CI, 0.38-0.87), and the pooled specificity was 0.82 (95% CI, 0.75-0.87). The pooled positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were 3.7 (95% CI, 2.1-6.3), 0.4 (95% CI, 0.18-0.91), and 9 (95% CI, 2-33), respectively. The area under the curve of PET/CT to detect BMI in FL patients was 0.83 (95% CI, 0.8-0.86). Current evidence suggests that PET/CT cannot replace bone marrow biopsy to detect BMI, but it is still of partial clinical significance for the prognosis of patients with follicular lymphoma.

Keywords: Bone marrow involvement; Follicular lymphoma; Meta-analysis; Positron emission tomography.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Biopsy
  • Bone Marrow / pathology
  • Fluorodeoxyglucose F18
  • Humans
  • Lymphoma, Follicular* / diagnostic imaging
  • Positron Emission Tomography Computed Tomography

Substances

  • Fluorodeoxyglucose F18